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and one man on replacement with growth hormone. No 
relations were seen between hormonal levels and injury 
variables.
Conclusions Perturbations in pituitary function continue to 
occur during the first year after TBI and SAH, but only a 
few patients need replacement therapy. Our study could not 
identify a marker of increased risk of pituitary dysfunction 
that could guide routine screening. However, data demon-
strate the need for systematic follow-up of pituitary func-
tion after moderate or severe TBI or SAH.
Keywords Pituitary · Hormone disturbance · Traumatic 
brain injury · Subarachnoidal haemorrhage
Introduction
Traumatic brain injury and subarachnoid haemorrhage may 
cause permanent physical, cognitive, behavioural and psy-
chosocial disabilities limiting daily activities [1–4]. With 
annual incidence rates from 235 to 538 cases per 100,000 
inhabitants [5, 6] for TBI and of SAH from 2 to 23 cases 
per 100,000 inhabitants [7, 8], these injuries correspond to 
huge human and economic costs and offer significant chal-
lenges both with regard to acute care and follow-up.
There is accumulating evidence that specialised neu-
rorehabilitation may enhance recovery and long-term out-
come after acquired brain injury [9–12] and also that this 
should start in parallel with the acute care [13] in order to 
prevent secondary complications and enhance functional 
improvement.
Several medical complications, such as infection, hydro-
cephalus, respiration problems (tracheostomy), nutri-
tion problems and heterotopic ossification may interfere 
with the post-acute rehabilitation process [14], while this 
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remains unclear for endocrine dysfunction. Disturbed pitui-
tary function has recently been highlighted as one poten-
tial factor that deserves attention and potentially treatment 
during neurorehabilitation [15–23]. However, until now, 
there is no consensus about either the prevalence, type or 
the clinical impact of pituitary disturbances after TBI and 
SAH and current recommendations for screening of pitui-
tary function and replacement therapy are debated [24].
After TBI, some degree of post-traumatic hypopitui-
tarism (PTHP) has been observed in 10–58 % of patients 
[16–18, 23, 25–29]. Several factors may affect the preva-
lence of PTHP including the time interval between TBI and 
evaluation of pituitary function, the severity of the injury 
and the diagnostic tests used [30]. In the chronic phase fol-
lowing TBI, growth hormone (GH), adrenocorticotrophic 
(ACTH), gonadotropin, and thyroidal deficiency as well 
as diabetes insipidus (DI) have been reported [16–18, 23, 
25–28].
There are some corresponding studies of hormonal dys-
function after SAH and these reports on GH insufficiency, 
adrenal, gonadotropin, and thyroidal deficiency [19, 21, 22, 
31]. The results of these are variable and even conflicting 
[19, 21, 22, 31–35] probably reflecting similar factors as 
discussed for TBI studies [30].
We have previously reported that pituitary deficien-
cies occur in a substantial number of patients early after 
TBI and SAH [36]. The aim of the current study was to 
evaluate the prevalence and course of pituitary function in 
patients during the first year after traumatic brain injury or 
subarachnoid haemorrhage and also to explore the relation 
between pituitary function and injury variables.
Materials and methods
This report is based on prospectively collected data 
from a consecutive cohort of patients, admitted to the 
Neurointensive care unit (NICU) at Karolinska Uni-
versity Hospital from 1 March 2009 until 30 June 2012 
after TBI or SAH. Patients were included at the NICU 
and followed at the Department of Rehabilitation Medi-
cine at Danderyd University Hospital, Stockholm Swe-
den, at 3, 6 and 12 months post-injury/illness. Hormone 
testing was performed at Department of Endocrinol-
ogy, Karolinska University Hospital. Inclusion was not 
performed during holidays for logistic and administra-
tive reasons. Inclusion required a moderate or severe 
TBI or SAH due to a ruptured aneurysm, a lowest GCS 
score during the first day after the event of 3–13, age 
≥18 years, living in the Stockholm region and obtained 
informed consent. For patients, who were unconscious 
or otherwise unable to give informed consent, the clos-
est relative was asked.
The study was approved by Regional Ethical Review 
Board in Stockholm (No: 2008/3:9 2008/1574-31/3).
Data collection
Demographic data (age, sex and smoking status), clinical 
and radiological parameters were prospectively collected 
from medical records at the NICU, Department of Reha-
bilitation Medicine and Department of Endocrinology, and 
transferred to the study data base.
Severity grading
In addition to the GCS score [37] (3–8 severe injury, 9–13 
moderate injury), clinical severity in patients with SAH 
severity was graded according to the Hunt–Hess scale 
(HH) [38]: 1, asymptomatic or minimal headache, nuchal 
rigidity; 2, moderate to severe headache, no neurological 
deficit except for cranial nerve palsy; 3, drowsiness, con-
fusion, mild focal deficit; 4, stupor, moderate to severe 
hemiparesis, early decerebrate; 5, deep coma, decerebrate 
posturing, moribund appearance. Aneurysms were verified 
by computed tomography angiography (CTA) or digital 
subtraction angiography (DSA). Aneurysms were divided 
into aneurysm from the anterior cerebral circulation and the 
posterior cerebral circulation.
Computed tomography (CT) lesion [39] grading of TBI 
was according to the CRASH model [40]: presence of one 
or more petechial haemorrhages (cerebral contusions), 
obliteration of the third ventricle or basal cisterns, suba-
rachnoid bleed, midline shift >5 mm, and non-evacuated 
haematoma (subdural/epidural). Brain oedema, basilar 
skull fractures and facial fracture were added to the CT 
model.
CT grading of SAH was according to Fisher’s scale (1: 
no blood detected; 2: SAH less than 1 mm thick; 3: SAH 
more than 1 mm thick; and 4: intraventricular or parenchy-
mal blood with or without diffuse SAH [39].
Assessment of endocrine function
An ACTH stimulation test (Synacthen test) and analyses of 
thyroid function, free thyroxine (fT4), thyroid-stimulating 
hormone (TSH) and free triiodothyronine (fT3), were per-
formed 10 days post-injury or at discharge from NICU, 
if earlier. The lowest and highest serum osmolality and 
P-sodium values during this time period at NICU were also 
recorded.
After discharge from NICU blood was sampled at 3, 6 
and 12 months, between 8 and 10 am. Flowchart of blood 
samples is presented in Fig. 1. At 3, 6 and 12 months blood 
was analysed for thyroid function (fT4, TSH and fT3) and 
cortisol. At 6 and 12 months, additional analyses were 
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performed for insulin-like growth factor-1 (IGF-1), pro-
lactin, estradiol in females, follicle-stimulating hormone 
(FSH) in females, luteinising hormone (LH) in females, 
and testosterone in males.
The optimal time for measurement of prolactin, IGF-1 
and gonadal function after TBI and SAH is widely dis-
cussed. The time points 6 and 12 month were used in order 
to allow stabilisation of the pituitary function and thus also 
to allow relevant decisions on treatment.
At 3, 6 and 12 months post-TBI/SAH, P-sodium (P-Na) 
was measured and serum osmolality if P-Na level was 
below or above the normal reference range.
The protocol was designed according to our clinical 
experience and local resources. Thus, Synacthen test was 
performed in the Neurointensive care unit at 10 days when 
the patients were still in hospital. In contrast, measurement 
of basal cortisol was taken at 3, 6 and 12 months follow-
up when patients were seen in the Rehabilitation outpatient 
clinic for clinical evaluation. The limit set for the Syn-
acthen test at a morning cortisol <400 nmol/L was based 
on clinical experience combined with results from the lit-
erature [41–43].
ACTH stimulation test was performed by adminis-
tration of Synacthen (250 µg) intravenously (i.v.), and 
blood samples were drawn before and 30 min after 
injection for analysis of cortisol. A normal response 
to the Synacthen test was defined as cortisol at 30 min 
>550 nmol/L. The patients were arbitrarily divided in 
three subgroups according to the cortisol response to the 
Synacthen test; one group with a subnormal response, 
one group with a cortisol response between 550 and 
1000 nmol/L and one group with a cortisol response 
>1000 nmol/L.
To be able to manage the large amount of data and 
combinations of TSH, fT4 and fT3, hypothyroidism was 
defined as fT4 level below the normal reference range. Ref-
erence value for fT4 is presented in Table 1.
An age-dependent reference range (geometrical 
mean ± 2 SD) for IGF-1, independent of gender, was cal-
culated based on the equation for the regression line in 
all patients: 10log [IGF-1 (µg/L)] = 2.581–0.00693 × age 
(year), with SD = 0.120 [44].
A growth hormone-releasing hormone—arginine stimu-
lation test (GHRH-ARG) was performed in patients with 
IGF-1 <−2SD. GHRH-ARG stimulation test was per-
formed by administration of GHRH 1-29 (1 mg/kg up to a 
maximum of 100 mg) i.v. at 0 min and then the infusion of 
arginine hydrochloride (0.5 g/kg up to a maximum of 30 g) 
i.v. from 0 to +30 min and blood samples for GH evalu-
ation were taken every 15 min from −15 to +120 min. 
GH deficiency was presumed if GH—max was below 
11.5 mg/L [Body Mass Index (BMI) <25], 8.5 mg/L (BMI 
25–30), and 4.2 mg/L (BMI > 30) [45].
Gonadotropin dysfunction in post-menopausal women 
was defined as FSH, and LH or estradiol below the normal 
reference range, in pre-menopausal women in combination 
with amenorrhoea or oligomenorrhoea. The reference range 
for estradiol, FSH and LH is presented in Table 1.
Gonadotropin dysfunction in men was defined as tes-
tosterone below the normal reference range. The reference 
range of testosterone is presented in Table 1.
The reference range of prolactin, P-Na, serum osmolal-
ity, TSH and fT3 is presented in Table 1.
Analyses of cortisol, fT4, TSH, fT3, IGF-1, estradiol, 
FSH, LH, testosterone, GH, P-Na and serum osmolality 
were performed in the Department of Clinical Chemistry in 
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Karolinska University Hospital using routine commercial 
kits.
Pituitary insufficiency during the first year after TBI or 
SAH
Patients were divided in groups of those, who showed hor-
monal disturbance at first or last tests, and those who did 
not show such disturbance. First test were taken at 10 days 
(cortisol and thyroid hormones) or 6 months (IGF-1, gon-
adotropin and prolactin). Last tests were taken at 12 months 
for all hormones.
We explore the relation between pituitary function and 
injury variables such the GCS score, pupil size or light 
reaction, peak of S100B (12–36 h), and hospitalisation 
length on the Neurointensive care unit for both TBI and 
SAH patients, and Fisher grade, Hunter and Hess grade for 
SAH patients, and CT scan pathology for TBI patients.
Statistics
Statistical analysis was performed using IBM SPSS Sta-
tistics version 22 (IBM Corporation, Armonk, New York, 
USA).
This observational study reported frequencies as 
mean ± SD [range (min–max)] or number (per cent) or 
median (percentile) or median (min–max).
Nonparametric methods were used as data were not nor-
mally distributed according to Shapiro–Wilk’s test of nor-
mality. The Mann–Whitney U test was used for group com-
parisons of GCS, Hunt and Hess grade, Fisher grade and 
peak S100B (12–36 h). The Fisher’s exact test was used 
for comparisons of CT scan findings, pupil size at admis-
sion, pupil reaction to light stimulation at admission. The 
Wilcoxon Signed-Ranks test was used for comparison of 
hormone level. In all cases, significance level was set at 
p < 0.05.
The Mann–Whitney U test was used for non-response 
analysis with respect to these variables: age, BMI, GCS, 
Hunter and Hess scale, Fisher scale and peak S100B (12–
36 h). The Fisher’s exact test was used for non-response 
analysis with respect to gender.
Results
Study population
In total 127 patients, 82 with TBI and 45 with SAH were 
included in the study.
Ten patients with TBI and four with SAH died before 
3 months follow-up. Twelve patients with TBI and five 
with SAH declined further participation in the study. Four 
patients with TBI and one with SAH moved abroad. A 
flowchart and drop-out of patients with TBI and SAH are 
presented in Fig. 2.
Demographic and clinical characteristics
Of the 56 patients with TBI, 15 were women and 41 
men, mean age was 47.1 ± 16.6 years, 44 patients had a 
Table 1  Reference values for basal concentrations
P plasma, U unit
Reference values
TSH 0.4–3.5 mU/L (DxI)
fT4 8–14 pmol/L (DxI)
fT3 3.5–5.4 nmol/L (DxI)
Cortisol ≥400 nmol/L normal function
Cortisol (Synacthen test) >550 nmol/L normal function
Estradiol <600 nmol/L for follicular phase women
200–2000 nmol/L for mid-cycle phase 
women
300–1000 nmol/L for luteal phase women
<150 pmol/L for post-menopausal women
FSH 2.5–10.0 U/L for follicular phase women
4.0–14.0 U/L for mid-cycle phase women
0.7–8.5 U/L for luteal phase women
0.7–8.5 U/L for post-menopausal women
LH 1.8–12 U/L for follicular phase women
18–90 U/L for mid-cycle phase women
0.6–15 U/L for luteal phase women
18–78 U/L for post-menopausal women
Testosterone 10–30 nmol/L for men
Prolactin 3–27 µg/L for age <50 years women
3–20 µg/L for age >50 years women
3–13 µg/L for men
IGF-1 250–610 μg/L for ages 18–19 years men
210–600 μg/L for ages 18–19 years 
women
250–590 µg/L for age 19–20 men
220–550 µg/L for age 19–20 women
160–420 µg/L years 20–25 years
150–390 µg/L for ages 25–30 years
140–370 µg/L for ages 30–35 years
130–340 µg/L for ages 35–40 years
120–320 µg/L for ages 40–45 years
110–300 µg/L for ages 45–50 years
110–270 µg/L for ages 50–55 years
100–260 µg/L for ages 55–60 years
90–240 µg/L for ages 60–65 years
85–220 µg/L for ages >65 years
P-Sodium 137–145 mmol/L
Serum osmolality 280–300 mosmol/kg
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severe brain injury and 12 patients a moderate brain injury 
according to the admission GCS score (mean GCS score 
6.3 ± 2.9).
Of the 35 patients with SAH, 27 were women and 8 
men, mean age was 57.4 ± 9.9 years, 22 patients had 
severe and 13 patients a moderate brain injury according 
to the admission GCS score (mean GCS score 7.9 ± 4.2). 
Most frequent Hunt and Hess scores at admission were 4 
and 3. All patients had SAH visible on CT scan (Fisher 
grade 2–4). Data are displayed in Table 2.
Endocrine evaluations
Hypothalamus–pituitary–adrenal (HPA) axis
In the acute phase 22/54 (41 %) TBI and 9/35 (26 %) SAH 
patients had low levels of morning s-cortisol. Results from 
the ACTH test were available for 53 patients with TBI and 
34 patients with SAH. Six (11 %) patients with TBI and 
six (17 %) with SAH responded with subnormal increase 
in cortisol. Of these, five patients with TBI and all five 
patients with SAH had been treated with different types 
of steroids (methylprednisolone was used in the treat-
ment of high intracranial pressure, and hydrocortisone for 
pharyngeal swelling and betamethasone was used in a few 
patients with SAH in the treatment of brain oedema).
In 18/53 patients (34 %) with TBI and 19/34 patients 
(56 %) with SAH the cortisol response was very high rang-
ing from 1000 to 2000 nmol/L.
At 3 months follow-up 17/54 (32 %) TBI and 10/35 
(29 %) SAH patients had low levels of morning cortisol. 
Results from the ACTH test were available for 10 patients 
with TBI and for 7 patients with SAH. Three patients 
with TBI and none with SAH responded with subnormal 
increase in cortisol. None of the patients with TBI and SAH 
had an exaggerated cortisol response over 1000 nmol/L. 
Ten patients refused to do the test or did not show up at the 
appointment.
At 6 months follow-up 19/52 (37 %) TBI and 23/34 (68 %) 
SAH patients had low levels of morning cortisol. Results 
from the ACTH test were available for 16 patients with TBI 
and for 19 patients with SAH. Only one patient with TBI and 
one patient with SAH responded with subnormal increase in 
cortisol. None of the patients with TBI and one with SAH had 
an exaggerated cortisol response. Seven patients refused to do 
the test or did not show up at the appointment.
At 12 months follow-up 18/52 (35 %) TBI and 15/35 
(43 %) SAH patients had low level of morning cortisol. 
Results from the ACTH test were available for 11 patients 
with TBI and for 11 patients with SAH. Two patients 
with TBI and none with SAH responded with subnormal 
increase in cortisol. None of the patients with TBI and two 
patients with SAH had an exaggerated cortisol response. 
Eleven patients refused to do the test or did not show up at 
the appointment.
Replacement therapy was clinically indicated in two 
patients with TBI and cortisol insufficiency after 12 months 
follow-up.
Numbers of patients with insufficiency of the HPA axis 
after TBI and SAH at baseline and 3, 6 and 12 months fol-
low-up are displayed in Figs. 3 and 4.
Thyroid function
In the acute phase, biochemical hypothyroidism was seen 
in 13/55 (23.6 %) patients with TBI and in 8/35 (22.9 %) 
patients with SAH. Ten TBI patients with low fT4 had nor-
mal TSH, one had low TSH and one increased TSH. Four 
SAH patients with low fT4 had normal TSH, three had low 
TSH and one increased TSH.
Fig. 2  Flowchart of study 
participants
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Table 2  Baseline data of 
patients with traumatic brain 










Age, years 47.1 ± 16.6 (19–79) 57.4 ± 9.9 (28–76)
BMI 25.6 ± 4.8 (18.5–42.2) 25.7 ± 4.3 (20.3–36.5)
GCS 6.3 ± 2.9 (3–13) 7.9 ± 4.2 (3–13)
n (%) n (%)
Gender
 Male 41 (73.2 %) 8 (22.9 %)
 Female 15 (26.8 %) 27 (77.1 %)
Smokers 19 (34.5 %) 16 (45.7 %)
GCS
 Moderate (9–13) 12 (21.4 %) 13 (37.1 %)
 Severe (3–8) 44 (78.6 %) 22 (62.9 %)
Hunter and Hess grade
 1 1 (2.9 %)
 2 3 (8.6 %)
 3 14 (40.0 %)
 4 15 (42.9 %)
 5 2 (5.7 %)
Fisher grade
 1 0
 2 3 (8.6 %)
 3 8 (22.9 %)
 4 24 (68.6 %)
Trauma cause
 Traffic accident 25 (44.6 %)
 Fall 28 (50 %)
 Assault 2 (3.6 %)
 Other 1 (1.8 %)
CT scan
 Cerebral contusions 45 (80.8 %)
 Obliteration of the third ventricle or basal cisterns 15 (26.8 %)
 Subarachnoid bleed 45 (80.4 %)
 Midline shift >5 mm 21 (37.5 %)
 Subdural/epidural haematoma 48 (85.7 %)
 Brain oedema 12 (21.4 %)
 Basilar skull fractures 26 (46.4 %)
 Facial fracture 17 (30.4 %)
Aneurysm localisation
 Anterior cerebral circulation AACA
  Anterior communicating artery ACoA 15 (42.9 %)
  Middle cerebral artery MCA 8 (22.9 %)
  Anterior choroidal artery AChA 1 (2.9 %)
  Internal carotid artery ICA 3 (8.6 %)
  Pericallosal artery 1 (2.9 %)
Posterior cerebral circulation APCC
 Posterior communicating artery PCoA 3 (8.6 %)
 Basilar artery 1 (2.9 %)
 Vertebral artery 1 (2.9 %)
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At 3 months follow-up 4/54 (7.1 %) TBI and 1/35 
(2.9 %) SAH patients had low levels of fT4. All TBI 
patients with low fT4 had normal TSH, but one SAH 
patient had increased TSH.
At 6 months follow-up 2/52 (3.8 %) TBI and 1/34 
(2.9 %) SAH patients had low levels of fT4. All TBI and 
one SAH patients with low fT4 had normal TSH.








 Posterior inferior cerebellar artery PICA 1 (2.9 %)
AACA + APCC
 MCA + PCoA 1 (2.9 %)
BMI Body Mass Index (kg/m2)
Fig. 3  Numbers of patients 
with pituitary deficiency after 
TBI at baseline and 3, 6 and 
12 months follow-up
Fig. 4  Numbers of patients 
with pituitary deficiency after 
SAH at baseline and 3, 6 and 
12 months follow-up
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At 12 months follow-up 0/52 (0 %) TBI and 2/35 
(5.7 %) SAH had low levels of fT4.
All SAH patients with low fT4 had normal TSH.
Replacement therapy was not clinically indicated in any 
patient.
Numbers of patients with biochemical hypothyroidism 
after TBI and SAH at baseline and 3, 6 and 12 months fol-
low-up are displayed in Figs. 3 and 4.
Somatotropic function
At 6 months follow-up low levels of IGF-1 (<−2SD) were 
observed in 2/52 (4 %) of patients with TBI and in 3/34 
(9 %) patients with SAH.
At 12 months follow-up low levels of IGF-1 (<−2SD) 
were observed in 6/52 (12 %) patients with TBI and in 2/35 
(6 %) patients with SAH.
Dynamic assessment at 12 months follow-up using 
GHRH-ARG stimulation test in 4/6 TBI and 0/2 SAH 
patients showed that one patient with TBI had growth hor-
mone deficiency (GHD).
Only this patient received replacement with growth hor-
mone after 12 months follow-up.
Number of patients with low IGF-I levels (somatotropic 
dysfunction) after TBI and SAH at baseline and 3, 6 and 
12 months follow-up are displayed in Figs. 3 and 4.
We also observed a high level of IGF-1 (>+2SD) in 9/52 
(17 %) patients with TBI and in 4/34 (12 %) patients with 
SAH at six months and in 7/52 (14 %) patients with TBI 
and in 1/35 (3 %) patient with SAH at 12 months.
Gonadotropin function
At 6 months follow-up, low testosterone levels were 
observed in 12/37 (32 %) patients with TBI and in 3/8 
(38 %) patients with SAH. At 12 months follow-up low tes-
tosterone levels were observed in 9/39 (23 %) patients with 
TBI and in 3/8 (38 %) patients with SAH.
Replacement therapy with testosterone was clinically 
indicated in two patients with TBI and two patients with 
SAH after 12 months follow-up.
At 6 months follow-up low FSH and low LH or low 
estradiol levels were observed in 2/15 (13 %) women with 
TBI and in 11/26 (42 %) women with SAH. At 12 months 
follow-up low FSH and low LH levels were observed in 
2/13 (15 %) women TBI and in 5/27 (19 %) women with 
SAH.
In post-menopausal women with gonadotropins insuffi-
ciency oestrogen therapy was not initiated.
Number of patients with gonadal dysfunction after TBI 
and SAH at baseline and 3, 6 and 12 months follow-up are 
displayed in Figs. 3 and 4.
Prolactin
At 6 months follow-up, low prolactin levels were observed 
in 1/52 (2 %) patient with TBI and in 1/34 (3 %) patient 
with SAH. At 12 months follow-up, low prolactin levels 
were observed in 2/51 (4 %) patients with TBI and in 0/35 
(0 %) patients with SAH.
At 6 months follow-up, high prolactin levels were 
observed in 3/51 (6 %) patients with TBI and in 0/34 (0 %) 
patients with SAH. At 12 months follow-up high prolactin 
levels were observed in 4/51 (8 %) patients with TBI and in 
4/35 (11 %) patients with SAH.
Antidiuretic hormone
In the acute phase 63/84 (75 %) of patients with TBI and 
40/46 (90 %) of patients with SAH had P-Na > 146 and 
serum osmolality >300 mosm/kg. Of these 9 TBI and 9 
SAH patients had been treated with fludrocortisone, and 7 
patients with TBI and 10 with SAH had been treated with 
desmopressin.
In 10/82 (12 %) patients with TBI and in 2/46 (4 %) 
patients with SAH a low P-Na in combination with a low 
serum osmolality was observed. Both patients with SAH 
lost in weight (−6.1 to −1.4 kg) while six patients with 
TBI lost weight (−7.3 to −1.1 kg) and four increased in 
weight (+1.5 to +7.1 kg).
Transient perturbations in P-Na, serum osmolality and 
body weight were seen in a few patients during follow-up 
but the number of patients was too few to draw any sta-
tistical conclusions. Only short-term interventions were 
required in these patients.
Relations between pituitary insufficiency during  
the first year after TBI or SAH and acute injury 
characteristics
Seven/46 patients (15.2 %) with TBI and four/30 patients 
(13.3 %) with SAH had an insufficient response to ACTH 
stimulation during the first year after TBI or SAH. Data 
from 10 TBI and 5 SAH patients were missing.
There were no significantly differences between patients 
with or without cortisol a sufficient response with regard to 
injury variables for both TBI and SAH patients. Data are 
displayed in Table 3.
Twelve/51 patients (23.5 %) with TBI and nine/35 
patients (25.7 %) with SAH had low levels of fT4 during 
the first year after TBI or SAH. Data from 5 TBI patients 
was missing.
Length of stay in NICU was longer for the TBI patients 
with low fT4 levels (p = 0.004) than in TBI patients with a 
normal thyroid function, but not for SAH patients.
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There were no significantly differences between patients 
with or without low fT4 levels with regard to others injury 
variables for both TBI and SAH patients. Data are dis-
played in Table 4.
Six/48 patients (12.5 %) with TBI and four/34 patients 
(11.8 %) with SAH had low IGF-1 during the first year 
after TBI or SAH. Data from 8 TBI and 1 SAH patients 
were missing.
A higher peak of S100B (12–36 h) was noticed in TBI 
patients with low IGF-1 (p = 0.003) than in TBI patients 
with a normal IGF-1, but not for SAH patients.
There were no significantly differences between patients 
with or without low IGF-1 with regard to others injury vari-
ables for both TBI and SAH patients. Data are displayed in 
Table 5.
Sixteen/48 (28.6 %) with TBI (3 women, 13 men) and 
14/34 (40 %) with SAH (10 women, 4 man) developed 
gonadotropin insufficiency during the first year after TBI or 
SAH. Data from 8 TBI and 1 SAH were missing.
The GCS score was lower in SAH patients with gonado-
tropin insufficiency (p = 0.022) than in SAH patients with 
a normal gonadotropin, but not for TBI patients.
There were no significantly differences between patients 
with or without gonadotropin insufficiency with regard to 
others injury variables for both TBI and SAH patients. Data 
are displayed in Table 6.
Two/47 patients (4.3 %) with TBI and one/34 patient 
(2.9 %) with SAH had low prolactin during the first year 
after TBI or SAH. Five/47 patients (10.6 %) with TBI and 
four/34 patients (11.8 %) with SAH had high prolactin dur-
ing the year after TBI or SAH. Data from 10 TBI and 1 
SAH patients were missing.
Non‑response analysis/bias
We found no significant difference in gender, age, BMI, 
GCS, Hunter and Hess and Fisher scale in participants with 
missing data for each hormone group.
Discussion
In the present study, we found that although perturbations 
in pituitary function are frequent early after the event, they 
Table 3  Relations between cortisol dysfunction during the first year after TBI or SAH and acute injury variables
q25–q75 quartiles 25 and 75, respectively
a n = 2
TBI SAH
Cortisol dysfunction Normal cortisol function Cortisol dysfunction Normal cortisol function
n = 7 n = 22 n = 4 n = 7
Median (q25–q75) Median (q25–q75) Median (q25–q75) Median (q25–q75)
GCS 7.0 (7.0–8.0) 5.5 (3.0–10.0) 8.0 (3.0–13.0) 8.0 (5.0–13.0)
Hunter and Hess 3.0 (3.0–3.75) 3.0 (2.0–4.0)
Fisher scale 4.0 (4.0–4.0) 4.0 (3.0–4.0)
Peak of S100B (12–36 h) 0.43 (0.22–0.64) 0.30 (0.19–0.50) 0.37a 0.23 (0.13–0.24)
Length of stay in NICU 33.0 (20.0–35.0) 20.0 (9.0–27.5) 23.5 (16.8–31.0) 19.0 (13.0–26.0)
Table 4  Relations between thyroidal dysfunction during the first year after TBI or SAH and acute injury variables
** p < 0.01
TBI SAH
Thyroidal dysfunction Normal thyroid function Thyroidal dysfunction Normal thyroid function
n = 12 n = 33 n = 9 n = 20
Median (q25–q75) Median (q25–q75) Median (q25–q75) Median (q25–q75)
GCS 7.0 (4.5–10.25) 5.0 (3.5–8.0) 5.0 (3.0–7.0) 8.0 (4.25–13.0)
Hunter and Hess 4.0 (3.0–4.0) 3.5 (3.0–4.0)
Fisher scale 4.0 (3.5–4.0) 4.0 (3.0–4.0)
Peak of S100B (12–36 h) 0.36 (0.20–0.51) 0.30 (0.17–0.49) 0.24 (0.11–0.31) 0.09 (0.06–0.22)
Length of stay in NICU 27.0 (20.3–35.8)** 18.0 (8.5–21.0) 20.0 (16.0–35.0) 16.0 (12.25–24.0)
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tend to wear off even though some persist or even occur 
later during the first year after TBI and SAH. The hormonal 
levels were very varying and low as well as high levels of 
all hormones were observed. However, in most cases, the 
changes in hormone levels were transient and without clini-
cal relevance. Thus, in total, 7 out of 95 patients required 
hormonal replacement (4 testosterone, 1 growth hormone, 
2 hydrocortisone) after 12 months while none needed treat-
ment for hormonal hypersecretion. None of the patients had 
pan-hypopituitarism.
Overall, our results are mainly in accordance with the 
findings in some previous studies of TBI [17, 18, 23, 
28]. E.g. Agha et al. [17] observed growth hormone defi-
ciency in 13 % of 50 patients at 6 months and in 10 % 
at 12 months; corresponding figures for adrenal insuf-
ficiency were 18 % at 6 months and 18 % at 12 moths, 
respectively; for gonadotropin deficiency 23 % and 13 %, 
for thyroidal deficiency 2 % and 2 % at these time points, 
respectively. Tanriverdi et al. [18] observed hyposoma-
totropism, hypocortisolism, hypogonadism and hypo-
thyroidism in 38, 19, 8 and 6 % of 52 patients at twelve 
months after TBI. Klose et al. [23] observed pituitary 
insufficiency in 76 % of 46 patients in the early phase 
post-injury, in 13 % at 3 months and 6 months post-injury, 
and in 11 % at 12 months. Bavisetty et al. [28] observed 
in 70 patients at 3 months and 6–9 months post-TBI major 
hormonal deficits in 25 % and 21 %, respectively, in the 
somatotroph, gonadotroph, thyrotroph, corticotroph axis.
Similarly, our findings are roughly in accordance with 
previous studies after SAH. Tanriverdi et al. [19]. observed 
GH deficiency in 36 % of 22 patients at 12 months after 
SAH and deficient adrenocorticotrophic hormone (ACTH) 
in 14 %. Furthermore, in 84 patients, Khajeh et al. [22] 
found gonadotropin deficiency in 20 and 5 % and GH defi-
ciency in 10 and 5 % at 6 and 14 months, respectively, after 
SAH. A recent study by Kronvall et al. [21] of 60 patients at 
6–12 and at 12–24 months after SAH. At these time points, 
they observed ACTH deficiency in 20 and 11 %, GH dys-
function in 20 and 29 %, and gonadotropin dysfunction in 2 
and 11 %, respectively.
Thus, our study as well as previous studies demonstrates 
that pituitary perturbations are most common early after the 
Table 5  Relations between somatotropic dysfunction during the first year after TBI or SAH and acute injury variables










n = 6 n = 33 n = 6 n = 25
Median (q25–q75) Median (q25–q75) Median (q25–q75) Median (q25–q75)
GCS 6.5 (4.75–7.25) 7.0 (4.0–9.0) 5.5 (3.0–11.75) 6.0 (3.5–13.0)
Hunter and Hess 3.0 (1.25–4.0) 3.0 (3.0–4.0)
Fisher scale 3.0 (2.0–4.0) 4.0 (3.5–4.0)
Peak of S100B (12–36 h) 0.61 (0.53–1.22)** 0.28 (0.17–0.47) 0.10 (0.04–0.22) 0.21 (0.08–0.33)
Length of stay in NICU 17.0 (11.0–29.0) 16.0 (6.5–28.0) 14.0 (11.5–15.0) 19.0 (15.0–27.0)
Table 6  Relations between gonadotropin dysfunction during the first year after TBI or SAH and acute injury variables










n = 16 n = 32 n = 14 n = 18
Median (q25–q75) Median (q25–q75) Median (q25–q75) Median (q25–q75)
GCS 5.5 (3.0–9.5) 7.0 (4.25–8.75) 12.0 (5.0–13.0)* 5.0 (3.0–8.0)
Hunter and Hess 3.0 (3.0–4.0) 4.0 (3.0–4.0)
Fisher scale 4.0 (3.0–4.0) 4.0 (3.0–4.0)
Peak of S100B (12–36 h) 0.45 (0.15–0.56) 0.29 (0.18–0.53) 0.15 (0.07–0.28) 0.21 (0.09–0.29)
Length of stay in NICU 17.0 (9.5–24.5) 19.0 (9.0–26.5) 17.5 (14.5–30.0) 19.0 (14.5–23.0)
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injury but may occur in a substantial proportion of patients 
at later stages. Obviously, prevalence figures differ between 
studies and this probably reflects differences in study sam-
ples as well as with regard to definitions of pituitary hypo-
function and analyse methods [23].
The most frequent pituitary insufficiency at the 1 year 
follow-up, observed in approximately one fourth of the 
patients in our study, was hypogonadotropic hypog-
onadism. Generally, the frequency of insufficient hormonal 
levels declined during follow-up and replacement was only 
clinically relevant in a few patients. This is in contrast to 
the findings in some earlier studies, reporting higher fre-
quencies, which could be due to differences in defining 
pituitary hypofunction, differences in the analyses of hor-
mones and differences in study samples.
In our study, we also observed periodic increases in hor-
mone levels as well as high stimulated levels of cortisol 
after ACTH injection. The high responses to ACTH stim-
ulation could indicate a persistent stress in these patients 
as also indicated by the high prolactin level seen in some 
patients. Of notice, high responses in the TBI group was 
only seen during the first three months after the event, 
while high responses in the SAH group was also seen 6 
and 12 months after the event indicating a more persisting 
stress in patients with SAH.
During follow-up, the frequency of patients with per-
turbations in hormonal levels in our study was similar 
for patients with TBI or SAH, indicating that the affec-
tion of the pituitary function was not dependent on aetiol-
ogy. These conditions may share some pathophysiologi-
cal mechanisms such as vascular support of the pituitary 
[46–48].
Although this study is subject to limitations, we believe 
it adds some valuable information to the existing literature 
and that one strength of our study is the comprehensive and 
long-term data collection. Consistent data now demonstrate 
that affection of pituitary function is most frequent in the 
early phase after the TBI and SAH and declines during 
the following months [5–7, 10, 11]. Only a small propor-
tion of patients with moderate or severe TBI or SAH need 
replacement therapy but these patients must be diagnosed 
and treated.
Unfortunately, we did not find an injury marker that 
could help identify patients at risk and thus to support a 
routine for selective screening of pituitary function. We 
investigated only a few injury markers and believe this is 
an important area for further studies. Recently, Zheng et al. 
[49] suggested that pituitary apparent diffusion coefficient 
(ADC) is a sensitive and independent marker of pituitary 
damage following TBI and others have started to investi-
gate genetic markers [50].
However, taken together with previous reports, we find 
it justified to suggest that all patients with moderate or 
severe TBI or SAH should be routinely screened at least 
at one time point after the injury and that screening around 
1 year after the injury may be considered a minimal obli-
gation. However, screening of the HPA axis, TSH-thyroid 
axis and FSH/LH-sex hormones every third month until 
12 months and of GH-IGF-1 at 12 months after the event 
may well be considered. Further, testing when there is 
clinical suspicion should be liberal. Obviously more stud-
ies are needed in order to develop evidence-based guide-
lines in this area. The potential impact of pituitary pertur-
bations on the long-term outcome after TBI and SAH also 
need further attention.
Study limitations
Regarding drop-outs and missing data, there is a risk of 
underestimation of pituitary disturbances in our study sam-
ples. However, most participants had some further contact 
with the study team as well as with other caregivers, and 
clinically significant insufficiency might then have been 
suspected and diagnosed.
The GHRH-ARG stimulation test was only performed 
in patients with S-IGF-1 < −2SD. This might potentially 
increase the risk of underestimating growth hormone 
deficiency which might in addition be underestimated in 
patients with hypothalamic damage.
Conclusions
Perturbations in pituitary function continue to occur during 
the first year after TBI and SAH, and low as well as high 
hormonal levels are seen. The changes in hormone levels 
are often transient and without clinical relevance. Thus, 
1 year after TBI in total 7 out of 95 patients needed hormo-
nal replacement. However, it is important to realise that a 
persistent hypofunction of the pituitary requiring hormonal 
replacement might occur in a minority after TBI or SAH. 
This has to be considered in the clinical management of 
these patients although there is still a need for more data to 
allow evidence-based guidelines.
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